Ben McKenna opens up on extent of his past gambling addiction – Bradford Telegraph and Argus

Posted on by

A FORMER Bradford (Park Avenue) player has revealed his own past gambling addiction as he tackles a charity trek to help others.

Ben McKenna, who had two spells with Avenue, will walk 80km, including all of the Yorkshire Three Peaks and then back to his home in Burnley all on this Saturday, in aid of the Gambling With Lives charity, which aims to raise awareness of the dangerous effects of gambling on mental health and high suicide risk.

The left-winger, 27, says gambling gripped his life for four years from 21 until he had a 'lightbulb moment' and placed his final bet almost two years ago.

He estimates he lost between 15,000 and 20,000 through online betting alone on roulette, football matches and horse racing in addition to losing money in bookies.

Ben McKenna says he is a happier man after ditching his betting past

McKenna, who made 41 appearances for Avenue, scoring eight goals in 2016 and then in the 2018-19 season, said: "It's a long way, I'm going to give it a go. I will be doing it on my own.

"I'll pace myself when I do it. I wanted to set myself something that's a bit of challenge. I want to push myself.

"Between 21 and 25, the betting was becoming a problem. They call gambling a hidden addiction. The signs are not visible like they are with drinking or drugs.

"I had about 10 online betting accounts at one point.

"I don't know what I spent at the bookies over the years. I was taking out loans, pawning jewellery.

I thought I was betting to win money, but it gave me a buzz. It was a rush.

"I thought if I wasn't prepared to help myself no-one else would help me.

"My biggest lessons was taking responsibility and accountability for my actions. Life has just got better now. I'm human, we all make mistakes.

"I had a bit of a lightbulb moment with the gambling on July 22, 2018.

"I remember driving to work one morning, parking up my car and thinking 'I'm better than that, I'm not having it'.

Ben McKenna's 'lightbulb moment' tattoo he had after placing his last bet in 2018

"The last time I placed a bet was on September 5, 2018. I would say I have overcome my gambling.

"Having my problems with gambling was the best thing that could have happened to me as I would not be the man I am today without that bad experience.

I am not ashamed of anything, I am proud of who I am now.

"People message me all of the time about their gambling and I go above and beyond to help people out. I want to try to turn my negative into a positive."

McKenna, who now plays for National League North side Spennymoor Town, says he looks back fondly at his time at the Horsfall Stadium and remains in touch with Avenue's current manager, Mark Bower.

He added: "It just stopped when I joined Avenue for the second time. That was coming towards the end of it.

I loved it at Avenue. I will always have a soft spot for Bradford. I still speak to the manager.

"I feel like I have created a new life for myself. I love walking now, it clears my head."

Go to justgiving.com/crowdfunding/bmckenna to make a donation or for more information.

See the rest here:

Ben McKenna opens up on extent of his past gambling addiction - Bradford Telegraph and Argus

The Memorial Odds, Picks, Winners and Prop Bets – The Sports Gambling Podcast

Posted on by

For those who missed it, please check out The Memorial Preview and Betting Strategies column for the types of golfers you should look to target for your bets.

With that in mind, heres who I like this week at Muirfield Village (with odds courtesy ofMyBookie.ag).

RELATEDThe Memorial Invitational Fantasy Golf Picks, DraftKings Targets

Rory McIlroy 14/1 (+160): Hes been pretty flat since the PGA Tour restart, especially for his standards. While he hasnt missed a cut he hasnt been very sharp with his irons as hes lost 0.06 strokes with them in his last three tournaments. Thats almost 0.7 strokes per round worse than his average since the beginning of the year. Hes being overshadowed this week by guys like Bryson DeChambeau, Patrick Cantlay and Justin Thomas, and like the aforementioned Justin Thomas last week it feels like a get right week for Rory.

Jon Rahm 22/1 (+225):Has Jon Rahm broken out of his ball-striking slump? Last week at the Workday was his best performance with his irons since the return of the PGA Tour, where gained just over a shot per round with them on the field. His putting, which had carried him early in the year to good finishes, continues to cost him. Should that return and he can maintain the momentum tee-to-green that he found last week, he should be right in the mix for a win. Hes long overdue for a win on the PGA Tour, and the pieces might be starting to come together for him.

Xander Schauffele 28/1 (+275):Im putting money on Xander with a smidge of hesitation. While he had a fantastic week with his irons at the Workday, he gained a vast majority of his strokes on the field with his putting. Hes been putting out of his mind since the PGA Tour returned to action, far outpacing his performances from early in the year. Theres some concern that might regress, but if it doesnt and hes a little better off the tee he could be in for a long overdue win.

Webb Simpson 28/1 (+275):Webb doesnt have a great history at Memorial, but he hasnt played this golf course since 2017. Hes a much improved and refined player tee-to-green since that time, and his game right now is a great fit for Muirfield Village. Hes even improved off the tee, gaining some length on his drives while still maintaining the accuracy that hes known for. Webbs definitely in line for his second win in three starts.

Others to Consider (with Top 20 Prop Odds)

Abraham Ancer 50/1 (+220):Ancer took a few weeks off but his ball striking is red hot, especially with his irons. Ancer is a fairly accurate driver off the tee and despite his short stature hes longer than you would think. Hes a nice sleeper to win the tournament for his first PGA Tour win.

Joaquin Niemann 70/1 (+225):Niemann sometimes is a forgotten man among all the young talent on the PGA Tour, but at his best hes just as good of a ball striker as the likes of Collin Morikawa or Viktor Hovland. Niemann had a great week tee-to-green last week at the Workday, only for his putter to cost him. A regression to the mean in that category should put him in the mix like he was at the RBC Heritage.

Lucas Glover 125/1 (+500):With such a strong field, its unlikely well get a super deep longshot winning this week. But if theres a guy who can pull the upset its Lucas Glover, whos ball striking has been on point since the PGA Tour returned. Glover has sniffed around the Top 20 in all four tournaments hes played since returning to action, only for his putting to cost him. With ball striking at such a premium this week, any sort of magic he can find on the greens would mean big things for his prospects.

Patrick Cantlay Top 10 (+160): While the results indicate a Top 10 for Patrick Cantlay last week, he was relatively anonymous most of the weekend at the Workday. Only a final round 65 was the reason why he vaulted up the leaderboard for a Top 10 finish. Everything seems to be in order for Cantlay to defend his title, but hes such a trendy pick this week and I cant help but wonder why he doesnt win more? For a player as consistent as him, he should be winning tournaments at a higher clip. In any event, while I dont like the 16/1 odds he has to win the tournament, I do feel hes a safe bet for another Top 10 finish.

Justin Rose Top 20 (+225):This is put up or shut up week for Justin Rose, and I think were about to find out what his trajectory the rest of this season is. Has his club change back to TaylorMade really helped? Or is he truly in a funk or possibly on the downside of his career. Im about done putting a futures bet on him to win, but I dont think hes as bad as what he showed last week. Justin Rose gets a stay of execution with my wallet, and I have a hunch he rebounds for a Top 20 finish at one of his strongest golf courses.

Other Top 20 Props to Consider: Tiger Woods (+120), Marc Leishman (+275), Paul Casey (+300), Harris English (+400), Doc Redman (+400), Corey Conners (+500), Harold Varner III (+600), Max Homa (+700), Nick Taylor (+800)

Patrick Reed Missed Cut +250: Patrick Reed seems like a trendy pick at 50/1 to win this tournament, but I have a nagging feeling hell fall short of expectations. Hes really struggling with both his ball striking and putting at the moment, and his T39 finish last week was all thanks to his scrambling as he gained over 4 shots on the field. Thats not a recipe for sustained success, and I think he misses the weekend.

Other Missed Cuts to Consider Ian Poulter (+200), Billy Horschel (+220), Kevin Kisner (+170), Jason Day (+160), Danny Willett (+140), Matt Wallace (+120)

Adam Hadwin over Ian Poulter (-110): Both tend to make their hay on the PGA Tour with their putting, but Hadwins ball striking has been a little bit better than Poulters over the last few weeks. In addition, Poulter gained just under nine shots on the field putting at the Workday, a clip that is begging to regress. Hadwin should beat Poulter head to head.

Joaquin Niemann +1.5 Strokes over Matthew Fitzpatrick (-130): I dont understand this line at all. Both finished T31 last week, but did it in completely different fashions. As mentioned above, Niemanns putting cost him a good ball striking week, while Fitzpatrick lost strokes off the tee and with his irons but was bailed out by his scrambling and putting. Niemann is primed for the positive regression, while Fitzpatrick is primed for negative regression. Niemann should be able to cover the 1.5 strokes.

RELATEDThe Memorial Invitational Fantasy Golf Picks, DraftKings Targets

Link:

The Memorial Odds, Picks, Winners and Prop Bets - The Sports Gambling Podcast

Roger Ver Contradicts 50% Report, Says Only 10% Of Bitcoin …

Posted on by

A recent report has shown that Bitcoin.com has laid off 50% of its staff. This was heavily covered by different news outlets. With the news coming out just days away from Bitcoin Cash halving, this was potentially disastrous for the project. The man behind it has sort to reassure holders. Roger Ver has come out to set the record straight. In a Reddit post, he has stated only 10% of his staff were fired.

Roger Ver has pointed out in his post that those reporting that he has let go of 50% in the last year are out to spread FUD. This especially with the Bitcoin Cash halving coming.

He noted;

Bitcoin.com had 84 people as of April 30, 2019, and now we have 76 people in April 2020,

He further explained to Decrypt in an interview that the layoffs were a result of Bitcoin Cashs price crash last year.

Vers response is however suspiciously timed with the halving now less than 48 hours away. This event is seemingly going unnoticed with Bitcoin Cash failing to rally.

Although it is at the time of writing this is up by more than 7%, it seems to largely be riding on the larger bullish wave sweeping the market. In fact, in the top ten, it is being outperformed by other coins such as Ethereum, EOS, and Tezos.

A majority of those commenting on Vers post is critical. The kindest have urged the man behind Bitcoin Cash that his response was unnecessary and Bitcoin.com, the company it is, should work efficiently and not be judged for letting go of inessential staff.

Others have gone another direction, like this one;

Lol, youre such a sleazebag. Comparing only to a handpicked metric. If you compare it to when the first company started you are up by many percentages. Just say how many employees you let go from the all-time high.

Whatever the number, it is clear that Bitcoin.com is not the company it used to be. Much of its glory has been lost and with the Bitcoin Cash halving also turning out to be a slump, if it fails to trigger a rally, and miners suffer a reward cut, this could turn Bitcoin Cash full-blown bearish. In a few years, Roger Vers work in the crypto industry could be in real trouble.

See the rest here:

Roger Ver Contradicts 50% Report, Says Only 10% Of Bitcoin ...

Roger Ver vows to fight new libel lawsuit from Craig …

Posted on by

LONDONRoger Ver, the CEO of Bitcoin.com, was served with a lawsuit today by Craig Wright for calling him a fraud and a liar in a YouTube videowhich has since been removed by YouTube.

Wright has been filing lawsuits against many people in the crypto space, including Peter McCormack, an anonymous Twitter user called Hodlonaut and Vitalik Buterin, co-founder of Ethereum.

Ver was served at a spontaneous London Bitcoin Cash meetup this evening. And Decrypt happened to be on the scene. So we asked if Ver will fight it.

Of course, he said. I think im going to put out another video calling him a fraud and a liar again, he told Decrypt, adding, Im not worried one bit. Im annoyed I have to spend some money on the lawsuit rather than hire one developer to build more tools to bring more economic freedom to the world.

Like many other critics, Ver said he disagreed with Wrights strategy of suing people in the crypto industry, which hes been doing in an apparent campaign to prove that he is Satoshi Nakamoto, the mysterious and anonymous inventor of Bitcoin.

Ver said that Wrights litigiousness was bad for Bitcoin SV, the cryptocurrency supported by the Australian computer scientist. A number of exchanges have delisted Bitcoin SV, to protest Wrights legal bullying, including Binance, Kraken and ShapeShift. However, Ver did not think this was necessarily the right response.

Indeed, he said he supported the Bitcoin SV project and people working with it but argued that this kind of bad press wont encourage its growth.

If youre busy suing everybody, people arent going to be your friend. Its that simple. Look at the lawsuits, all the exchanges that delisted SV, he said, adding that he felt the exchanges were behaving unfairly. I dont think it was a good thing. If people want to trade it, I think people should be able to trade it, he said. Free the market, free the world. If you want to trade Bitcoin SV, go for it.

More here:

Roger Ver vows to fight new libel lawsuit from Craig ...

UAB and Ascension St. Vincent’s plan health care alliance – Newsaegis

Posted on by

The University of Alabama at Birmingham Health System and Ascension St. Vincents have entered into a strategic alliance that will increase access to high-quality, innovative medical care through multiple outlets and health programs.

In January, the health systems announced their intention to form a strategic alliance and began a period of due diligence. The formal alliance began July 1.

Having received necessary approvals, including that of the University of Alabama System Board of Trustees and the Ascension Board of Directors, the new strategic alliance will enable the two entities, which have a long history of collaboration, to further enhance patient care and address Alabamas most challenging health threats. The strength of the collaboration between the two health systems has been on display throughout the COVID-19 pandemic, says Jason Alexander, CEO of Ascension St. Vincents and senior vice president of Ascension.

Our ability to coordinate our efforts in response to COVID-19 benefited each organization and the patients and communities we serve, Alexander said. Ascension St. Vincents was able to leverage our network to obtain personal protective equipment that was urgently needed by both systems but in short supply, and UAB has accepted the majority of the volume of COVID-positive patients. This alliance will now allow us to be able to collaborate even more.

UAB Health System CEO Will Ferniany says, now that the alliance is formalized, he looks forward to working with Alexander and the Alliance Board to ensure the alliance is a win-win for patients, the community and both organizations.

We have a great opportunity to improve health care delivery in Alabama for our patients and communities, and doing so will make each organization stronger, Ferniany said. Our physicians, staff and leadership are now better positioned to deliver on our community service-focused missions.

Ferniany and Alexander serve as the administrative leaders of the alliance Ferniany as CEO/president and Alexander as executive vice president with coordinated governance and administrative responsibilities.Both say that efficiencies created by the alliance will also strengthen each organization both clinically and financially.Though the two entities will share resources to better serve the community, they will maintain separate, yet aligned, operational structures.For example, the medical staffs will remain independent at each system. Medical staff privileges to work within each system would be obtained separately.The historic missions of the organizations will be preserved.Ascension St. Vincents remains a ministryof the Catholic Church, and UABHS remains an academic medical center with public, charitable and research functions.

The alliance will utilize innovative strategies to address health disparities, mental and behavioral health, and diabetes, with an emphasis on expanded access for poor, vulnerable and rural populations.

UABHS and Ascension St. Vincents leaders say the new alliance enhances their longstanding relationship and affirms each organizations ability to help patients receive the right care in the right setting at the right time.

As health care continues to evolve, it is important for health systems to work with each other to provide innovative, person-centered care, Ferniany said. It has always been our shared commitment with Ascension St. Vincents to remain on the forefront of this vital health care transformation.

UABHS facilities will retain the UABHS or UAB Medicine brands. Ascension St. Vincents facilities will continue to be branded as Ascension St. Vincents.

Original post:

UAB and Ascension St. Vincent's plan health care alliance - Newsaegis

Ed Lovern to Lead Ascension Saint Agnes in Baltimore – Patch.com

Posted on by

Following an extensive national search, longtime healthcare executive Ed Lovern, MHA, FACHE, has been selected to serve as Health System President and CEO of Ascension Saint Agnes in Baltimore, effective July 20. Ed is a transformational leader with more than 25 years of experience in executive roles with successful healthcare systems.

Ed currently serves as Chief Operating Officer at Piedmont Atlanta Hospital, flagship hospital of Piedmont Healthcare, an 11-hospital integrated healthcare system with more than 20,000 employees and annual net revenues of $3.1 billion. Piedmont Atlanta is a 643-bed tertiary hospital in a competitive urban market with annual net revenues of $1 billion.

Prior to his time at Piedmont, Ed was the Washington, D.C., Bureau Chief for Modern Healthcare magazine. Earlier in his career, he served in several leadership positions at Ascension Borgess in Kalamazoo, Michigan.

Ed earned a Master of Health Administration from Virginia Commonwealth University, Richmond, Virginia, and a Bachelor of Arts in Business/Economics from Randolph-Macon College, Ashland, Virginia. He has served on the boards of several community and non-for-profit organizations, including as Board Chair for Odyssey Family Counseling Center in College Park, Georgia, and Board member for Jewish Home Life in Atlanta and Rotary Club of Buckhead in the Atlanta metro.

"I am especially grateful for the leadership of the interim president of Ascension Saint Agnes, Chris Chekouras, and want to recognize the achievements of our Baltimore ministry over the past year," said Craig Cordola, MBA, MHA, FACHE, Executive Vice President and Chief Operating Officer, Ascension. "The efforts of our Ascension Saint Agnes caregivers in treating stroke patients again garnered national recognition in 2019 by the American Heart Association/American Stroke Association. The hospital is also playing an important role in plans by Baltimore County to accelerate its response to the opioid epidemic. In addition, Ascension Saint Agnes is working collaboratively with the city, community and local hospitals to address homelessness for vulnerable individuals and families. We wish Chris continued blessings as he leaves our ministry."

This search process was a collaboration among the Ascension Saint Agnes Board, the medical staff, and the leadership team who led this search process under the guidance of former Ascension Saint Agnes Board Chair Irene Knott, whose term ended June 30. "We are excited to have Ed join our ministry and know that his deep experience and commitment to our Mission, in partnership with Ascension Saint Agnes associates, caregivers and providers, will serve the community well as we provide care for those most in need," said John Wheeler, Board Chair, Ascension Saint Agnes.

Read the original here:

Ed Lovern to Lead Ascension Saint Agnes in Baltimore - Patch.com

Succession: Sarah Snook on the Ascension of Shiv Roy – IndieWire

Posted on by

There is a certain tragedy within Siobhan Shiv Roy, only daughter in the Logan Roy (Brian Cox) family empire. Arguably the smartest, savviest, most liberal member of the brood, Shiv still cant manage to avoid the emotional pitfalls that ensnare brothers Kendall (Jeremy Strong), Roman (Kieran Culkin), and Connor (Alan Ruck), no matter how much clear-eyed strategy she employs.

She is forever Wile E. Coyote to the Road Runner of her fathers affection, smart enough to devise foolproof plans to catch her prey, only to end up running head-first off of a cliff, time and time again.

In the stellar second season of HBOs Succession, Sarah Snook, the Australian actress who brings Shiv to life, found new layers to the character. Snook finds the nuance in a woman who is self-assured enough to know exactly what she wants, but still damaged enough to allow her plans to be completely derailed by the empty promises of her manipulative father. By the end of the season, Shiv is left in a place of uncertainty and not even Snook can say what her next move might be.

Shes pretty smart, Snook said of her character in a recent interview with IndieWire. Shes not going to take any shit, but shes also stuck between a rock and a hard place now, where Kendall goes out against [Logan], and she cant now align herself with Kendall because shes then second to him. She has to align herself with her dad in order to not be second, for the long-term.

And while Shiv is now soundly embroiled in her familys drama after spending so much of her life trying to hold herself above the fray thats not the only one of her relationships experiencing turbulence, as the Season 2 finale shows things might finally be boiling over with her newlywed husband Tom Wambsgans (Matthew Macfadyen). Luckily, those tensions are a far cry from what the actress experiences in real life with her fake husband.

Matthew is like one of my favorite, favorite humans, Snook said. Hes such a lovely, lovely man. And hes just so good at his job. So generous, so kind, so gentlemanly, so upstanding. And Tom is so different from that in so many ways. Not everyones capable of playing that, which is kind the kind of actor he is. Its amazing.

Zach Dilgard/HBO

We do together have a lot of fun doing our scenes, and I find them easy because you get to watch and listen to him and then it kind of all happens. And then we have some of the most outrageous things to say, which is really fun to play.

According to Snook, its not just scenes with Macfadyen that are a joy. Succession is the type of series that thrives when featuring a large portion of the ensemble, in no small part because the way the show is filmed captures so many background reactions and expressions too often either neglected or overlooked in other shows. The camera operators are so adept at their jobs that Snook said theyre keenly monitoring the actors movements at all times, seeing small things unfolding as the main action takes place.

You might not think a persons in the scene. They might not be in the regular setup, but anything is up for grabs, which I love, Snook said. And as an actress, its such a gift because it means when were on the schedule for a day, we will work. You will be doing something. You will be active. You will be in the scene, create. Your imagination is allowed to run wild. And then it feels more like its teamwork. Thats my favorite part of filmmaking.

Peter Kramer/HBO

Its all slightly unreal for the actress who was certain she didnt have a prayer of being cast when the project originally entered her radar. I read it and was like, Oh, well, Ill watch this. I want to know what happens after that final scene of the pilot episode, but obviously Im not going to be in it, so whatever, Im not going to audition, Snook said.

But when I first heard about it, I had some doubts. I didnt know what character she was likely to become. She could just become the kind of handbag, pretty face, sort of trotting around as the female member of the family, she said. And because of that, she goes to the sidelines, which women really face in this world. In reality theres still inequality in gender and gender pay gap and getting into business at that level. Clearly we see that within the show. And that wasnt something I was really interested in, if that was the case.

To their credit, yes, theyre showing the reality of it. Its a lot of white men in business at that level, but they are also willing to elevate and make interesting characters on the sides as well, and then Shiv had a chance to kind of crowbar that open, she said.

In Season 2, both the show and Snook established Shiv as a real power player, both within her family and the family business, and in the meantime sparked a lot of internet conversation about another recent development: Shiv Roy, fashion plate.

Its kind of crazy, because thats so far from what I am as Sarah. Im not a fashion icon by any means, in any stretch of the imagination, Snook laughed. It was weird, it was sort of unbelievable. Im sort going along and seeing people dress in that kind of costume. I was like, What? And then I was like, Oh, come on you just threw that outfit together because you got invited to a Halloween party, like, 10 minutes ago. But also, it was just super fun and I tripped out, seeing people dressed up as Shiv!

Sign Up: Stay on top of the latest breaking film and TV news! Sign up for our Email Newsletters here.

Here is the original post:

Succession: Sarah Snook on the Ascension of Shiv Roy - IndieWire

St. John the Divine and Other Local Churches Partially Reopen; One Bans Singing – westsiderag.com

Posted on by

Posted on July 14, 2020 at 2:14 pm by Carol Tannenhauser

St. John the Devine.

By Rene Roden

On July 14th, one of the Upper West Sides storied landmarks reopens its doors. The Cathedral of St. John the Divine announced that the Cathedral will reopen seven days a week, for individual prayer, reflection, and meditation.

Photo-snapping tourists are out of luck, but individuals seeking some solace in the historic Episcopalian sacred space will find the front doors open from 7:30 am to 1 pm each day.

There will be some conditions for admission to the Cathedral. In its press release, the Cathedral noted: Health screenings will be administered upon entrance, and masks and physical distancing will be mandatory. Visitors cell phone numbers and email addresses will be collected for contact tracing and communication purposes.

The Cathedral preemptively cancelled all large in-person services and events until the end of 2020. The Cathedral has made the difficult decision to cancel large in-person events and major services for the remainder of 2020 in an effort to mitigate the spread of COVID-19. The Cathedral anticipates resuming in-person services of worship and large-scale events after January 15, 2021 if allowed by governmental guidelines.

The Cathedral is allowing some services in person, next week. Small funeral and memorial services are also anticipated to resume beginning July 21.

Given that religious services at the Young Israel Congregation in New Rochelle sparked an early March super spreader event, houses of worship are cautious to avoid becoming new occasions for COVID transmission.

The Cathedral is not alone in charting a new course through the uncertain waters of public safety. Several Catholic churches on the Upper West Side have opened for in-person masses, their naves newly decorated with taped-off pews mandating a six-foot distance, markers on the floor, and hand sanitizer dispensers replacing Holy Water fonts.

Just four blocks south of the Cathedral, Ascension Church has remained open throughout the pandemic. Pastor Rev. Daniel Kearney said that their church building was rarely ever empty over these past few months.

Inside Ascension Church.

Ascension opened for Sunday masses July 5th, reducing their number of masses from seven to four. Their distinctive Sunday night jazz mass has been canceled throughout the rest of the summer. Rev. Kearney said usually Ascension sees between 1,200 and 1,400 people over the course of seven masses on a weekend.

But this past weekend, only two hundred people total attended Ascensions four masses. Kearney said the Archdiocese of New York calculated the government-mandated 25% capacity for each of the diocese churchs and Ascensions is 125. Kearney said each mass totaled well below that, and hovered around Ascensions independently calculated safe-capacity of 78 to 80.

A recent court case in Albany raised the cap from 25% to 50% capacity, but a spokesperson for the New York Catholic Conference stated that they would adhere to the previously mandated cap of 25% capacity.

Parishioners attending mass have been diligent about the rules, keeping social distance and wearing masks, Kearney attested. Ive found people to be very responsible, and just happy that theyre able to be back, he added.

A committee of six parishioners advised Kearney through the reopening process. Every two weeks they will re-evaluate the policy to ensure parishioner safety.

Redeemer West Side Church on 83rd has also re-opened its space for in-person services. Like St. John the Divine, Redeemer is mandating a contactless health screening prior to entry. According to its website, Redeemer is limiting attendees to 100 per service to ensure safe physical distancing. Worshipers will be required to register for the service they want to attend to ensure this.

One particular rule Redeemer instituted sets it apart from other congregations: they have banned singing.

New York recommends 12-foot distancing to allow singing, reads its online notice, and therefore we cannot allow congregational singing at this time. Feel free to stand, hum along, sway, but if you are attending in-person services, you will not be able to sing out loud.

Rev. Andrew Field, Executive Pastor of Redeemer West Side stated that the weeks of careful planning paid off for a smooth reopening weekend. The team definitely leans toward the side of extra caution, he said, they received advice from expert health professionals throughout the process. Field said that fewer than one hundred people attended s in a large, nearly 900 seat space that has high-quality airflow. Even though the service was conducted in-person he said, that most of our congregation participated at the same time online through our livestream.

St. Paul and St. Andrew United Methodist Church.

Some churches are remaining fully online but paying forward their empty sanctuaries. St. Paul and St. Andrew United Methodist Church on West End Avenue is delaying gathering in person for now. Rev. Lea Matthews, Associate Pastor, commented in an email that the Church is being put to other purposes.

The church building is fully functioning as a food distribution center for the West Side Campaign Against Hunger (the entire basement level and first floor of the church is laden with food and prep for that) and Goddard Riversides meals on wheels program.

She said the Church community has remained busy as ever with online worship, small spiritual support groups, racial justice programming, political education classes, and meetings, all conducted virtually. Their in-person focus at the church building has been keeping that holy and hard work happening with ease and as little risk as is necessary. She stated: We are being cautious and conscientious and do not plan to be gathering as a large group for quite some time.

All the reopened churches are continuing to live-stream services. Rev. Kearney expected that Ascension would live-stream services for the foreseeable future.

Original post:

St. John the Divine and Other Local Churches Partially Reopen; One Bans Singing - westsiderag.com

Ascension of the Watchers Announce New Album Apocrypha For October 2020 Release – mxdwn.com

Posted on by

Roy Lott July 10th, 2020 - 2:04 PM

Ascension of the Watchers will release their second full-length albumApocryphaon October 9 viaDissonance Productions.Apocryphas concept was visualized by frontmanBurton C. Bell, . The album had been in development for nearly a decade. With plans of touring, the band continues to grow as Bells main creative endeavor, well into the future. In 2018, the band decided to utilize the crowdfunding platform PledgeMusic to jumpstart the project. After a very successful campaign, raising 124% of their goal, PledgeMusic went into administration, but then declared bankruptcy and in turn, would never release any of the funds dedicated to Ascension of the Watchers.

Apocrypha follows their debutNuminosumreleased in 2008 and their most recentStormcrow, released last year. Also envisioned by Bell, it provided sonic textures, dark melodies and lyrical melancholy, remaining true to the concept of the fallen angels (The Watchers) fromThe Book Of Enoch.It was recorded at Northstone Studios, based in the countryside of South Wales, connected to the two-hundred-fifty year old Court Colman Manor, was built by Lewis own hands using the ancient stones of the monastery that once stood there.

Ascension of the Watchers formed in 2001 and consists ofBell,John Bechdel andEdu Mussi. Bell is also a former member of groove metal band Fear Factory.

Apocryphatrack listing:01.Ghost Heart02.The End Is Always The Beginning03.Apocrypha04.A Wolf Interlude05.Honore06.Stormcrow07.Cygnus Aeon08.Key To The Cosmos09.Bells Of Perdition10.Wanderers11.Sign Your Name

Here is the original post:

Ascension of the Watchers Announce New Album Apocrypha For October 2020 Release - mxdwn.com

ASCENSION OF THE WATCHERS sign with Dissonance Productions – XS ROCK

Posted on by

ASCENSION OF THE WATCHERSwill release their second full length albumApocryphaglobally on October 9. The recording will be available on cd, two limited vinyl formats and through all major digital outlets.

A creative, and innovative journey of pioneering vocalistBurton C. Bell. Their latest recordingApocryphais a vision untold.

Born of life, love and spirituality, Bells unmistakable, harmonious inventory once renowned in one of metals finest pioneering acts has brought life to a new concept, a genre of its own.

Ambient atmospheres, melodies and introspective lyrics that sheds light of Bells visions, as seen in their purest form. An intimate nature thatAscension of The Watchersenvisioned, to draw the minds, hearts and aspirations of a people to a higher level of thinking to a feeling with cohesive celebration and reflection in the beauty of existence.

In early 2002 Burton retreated to the quiet, simplicity of rural Pennsylvania for seven months with his friend and musical confidantJohn Bechdel, escaping the onslaught of Los Angeles, and industry alike. A mentor in music, philosophy and demeanour, Bechdel unwittingly guided Bell along the creative path of this new conceptual movement.

With Burtons unprecedented vocal sound and style, coupled with the brilliantly orchestrated musical compositions of both Bell and Bechdel (synonymous with pioneering tags to the industrial/metal genre) The pair began experimenting with textured melodies of melancholic tones, best attributed to the 80s and 90s underground scene.Ascension of the Watchersechoes the sounds of a prophetic hallucination, fears and dreams with remorse of things lost and forgotten; but with a hope of redemption and light in the future.

In 2004,Ascension of The Watchersindependently released Iconoclast,printed only on cd and vinyl to a limited number.

In 2008, with the help John Bechdel andPaul Raven(RIP), Burton broughtAscension of The Watchersto Ministry legend Al Jourgensens label,13th Planet. With the guidance and special collaborations with Jourgensen during the recording and mixing in El Paso, Texas, AoTW added the guitar talents of Eduardo Mussi. It also featured Paul Ravens last contribution as a bass player on the track Mars Becoming.

In 2008, Ascension of The Watcherss debut LP,Numinosum,was released through13th Planet. Upon release, AOTW performed special, intimate shows, including the album release performance at Alex Greys Chapel of Sacred Mirrors in NYC. They also had the honor of supportingKilling Jokefor their reunion tour in honor of their fallen friend, Paul Raven.

In 2017, the friendship between renowned UK solo artistJayce Lewisand Burton brought in the essential camaraderie, talents and studio that perfectly suited the recording ofApocrypha.

Northstone Studios, based in the countryside of South Wales, connected to the 250 year oldCourt Colman Manor, the studio built by Lewis own hands using the ancient stones of the monastery that once stood there, the rustic detail proved a perfect setting for AoTWs very ownJayce Lewisto record, produce and mix theApocryphaalbum. A recording process thatliterallystirred the souls that remain within the stone walls of LewisNorthstone Studios. During the vocal recordings of the title track, a recording was inadvertently captured from the aether; an eerie, unrecognizable and untranslatable, syllabic phrase whispered within the vocal booth. The event is now the intro to the title track,Apocrypha.

In truth, the making ofApocryphahas been a decade long journey of writing and recording, from California, Pennsylvania, New York and Wales. In 2018 the band decided to utilize the crowdfunding platform PledgeMusic to jumpstart the project. After a very successful campaign, raising 124% of their goal, PledgeMusic went into administration, eventually declaring bankruptcy! and in turn, would never release any of the funds dedicated toAscension of the Watchers. Nevertheless,Ascension of the Watcherspersevered to complete the album.

After ten years of writing and recording, along with reflection on the very personal nature of this project,Ascension of The Watcherswill renew its journey in 2020!With the culmination of the long awaited release Apocrypha.With plans of conceptualized touring, Ascension of the Watchers continues to grow as Bells main creative endeavor, well into the future.

Burton C. Bell Vocals & GuitarJohn Bechdel KeyboardsJayce Lewis Drums, Backing Vocals & Programming

From them I heard all things, and understood what I saw, that which will not take place in this generation, but in a generation which is to succeed at a distant period, on account of the elect.

All shall be afraid, and the Watchers be terrified. The Book of Enoch

Label:https://www.dissonanceproductions.co.uk/https://www.facebook.com/DissonanceProductionsUK/Twitter:https://twitter.com/DissonanceProds

Vinyl version released via Back On Black Records (Black and Clear double LP)www.backonblack.com

Related

Read more:

ASCENSION OF THE WATCHERS sign with Dissonance Productions - XS ROCK

After more than 6 years, this big Prairieville road project might be done in 2020 – The Advocate

Posted on by

A long-awaited project to widen a vital state highway through Prairieville that has sustained a myriad of delays will face just one more, parish officials say, before it's finished after more than six years.

The $27.5 million expansion of La. 42 is projected to be finished by the end of 2020 after delays from the novel coronavirus outbreak pushed back the previous finish date, which had been planned at Thanksgiving time, Ascension Parish President Clint Cointment said.

"Barring any other work stoppages due to unforeseen circumstances or adverse weather, the contractor is on schedule for opening all lanes of travel in late December 2020," parish officials said in a statement.

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

PRAIRIEVILLE Construction of a $27.5 million expansion of La. 42 in Ascension Parish started Monday and is expected to take more than two ye

When state highway and parish officials broke ground on the construction phase of the project in December 2017, the highway was then anticipated to be finished in the spring of 2020. The new delay is the latest in a series for a project that began in 2014.

The project has involved widening two-lane La. 42 to four lanes with a median across nearly 3.5 miles from Airline Highway to just past La. 44. The new wider highway has already largely taken shape, with J-turns for left turns and U-turns, a sidewalk and a bike trail. The new road, once finished, will have 11-foot-wide lanes.

Since the early 1990s, the area along La. 42 has grown into a suburban zone of a few retail shops and many new neighborhoods.

The highway project had been stymied for years from lack of funding and was handed off from administration to administration following a mid-1990s fatal crash that first prompted calls to widen the thoroughfare.

Once finished, the job will have missed its very first projected finish date by more than four years.

Preparatory work on the widening project has been underway since March 2014, when the state kicked off land clearing. At that time, state highway officials thought the entire widening project could be finished by the summer of 2016.

But work was tied up for three years in utility installations when parish government contractors were called in to lay down new sewer lines required for the road widening to proceed. The new wider La. 42 doesn't have open ditches along the highway, which had formerly received sewer discharges.

PRAIRIEVILLE Loretta Templet and Sherri LeBas hugged outside an Ascension Parish library along La. 42 shortly after LeBas, the Louisiana sec

Cointment noted the importance of La. 42 as an east-west corridor.

Parish officials said contractors are currently working on the median near a Rouse's grocery story and moving east and on curbing along the road's edge on other sections of the road.

Once enough curbing is installed, contractors will begin applying the nearly 15 inches deep of asphalt for the road surface.

Go here to read the rest:

After more than 6 years, this big Prairieville road project might be done in 2020 - The Advocate

Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration – BioSpace

Posted on by

BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the companys principal contract development and manufacturing partners, today announced that they have extended their collaboration initiated in April 2018 for a period of five years through June 2025.

With the extension of the collaboration, MolMed will continue to support activities related to the development and manufacturing of vectors and drug products for several of Orchards investigational ex vivo hematopoietic stem cell (HSC) gene therapies in the upcoming years, including OTL-200 for metachromatic leukodystrophy (MLD) and OTL-103 for Wiskott Aldrich syndrome (WAS), as well as for additional pipeline programs including OTL-203 for mucopolysaccharidosis type I (MPS-I). MolMed is the first company to have obtained good manufacturing practice (GMP) authorization for the gene and cell therapy markets in Europe and is the manufacturer for Strimvelis, Orchards ex vivo HSC gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) and the first such treatment approved by the European Medicines Agency (EMA).

We are looking forward to continuing to build and expand upon our partnership with MolMed, who have supported the progression of many of our programs since their earliest clinical development stages, said Frank Thomas, president and chief operating officer of Orchard. Their expertise in gene therapy manufacturing, coupled with their deep knowledge of our programs, will be invaluable as our therapies for MLD and WAS approach anticipated approval and commercialization in Europe and across the globe.

Luca Alberici, MolMed's chief business officer, added, "We are pleased to have strengthened our collaboration with Orchard to support them in their mission of bringing potentially transformative therapies to those suffering from severe rare diseases. After being Orchards exclusive manufacturer for Strimvelis, we are looking forward to supporting their manufacturing needs for additional programs both in clinical trials and in potential commercial applications following the anticipated approval of OTL-200 for MLD in Europe later this year.

OTL-200 for MLD is currently under review by the EMA with a decision expected later this year.

About OrchardOrchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

About MolMedMolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of novel cell and gene therapies. MolMed, established in 1996, has been listed since March 2008 on the Italian Stock Exchange managed by Borsa Italiana, and has its registered office in Milan, at the Biotechnology Department of Ospedale San Raffaele and an operating site at Bresso, at the OpenZone campus.

Availability of Other Information About OrchardInvestors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking StatementsThis press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release, Orchards expectations regarding the timing of regulatory submissions for or marketing approval of its product candidates, and Orchards expectations concerning its partnership with MolMed. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development and commercial programs; the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the risk of delays in Orchards ability to commercialize its product candidates, if approved; and the risk that Orchard may not receive the expected benefits from its collaboration with MolMed or that Orchard or MolMed will not fully perform under the terms of their collaboration agreement. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter ended March 31, 2020, as filed with the U.S. Securities and Exchange Commission (SEC) on May 7, 2020, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Orchard Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaMolly CameronManager, Corporate Communications+1 978-339-3378media@orchard-tx.com

MolMed Contacts

Investor Relations & Communications DepartmentMolMed S.p.A.+39 02 21277.205investor.relations@molmed.com

Tommasina CazzatoPress OfficeCommunity Group+39 345 7357751tommasina.cazzato@communitygroup.it

Read more here:

Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration - BioSpace

Gilead axes $445M Precision Biosciences gene therapy hep B pact – FierceBiotech

Posted on by

Gilead Sciences is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.

Back in September 2018, Gilead laid up to $445 million on the table in biobucks that saw the pair collaborate on gene therapies aimed at eliminating viral infections in vivo by using Precisions genome editing platform.

Under the deal, Gilead was on tap to fully fund the effort and run clinical trials while Precision was on the hook for early development, formulation and preclinical work.

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Inks intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

Current HBV treatments may suppress viral replication, but they do not completely clear out the virus; the infections covalently closed circular DNA, or cccDNA, enables HBV replication to restart if treatment is stopped.

Precisions ARCUS editing platform is derived from a natural enzyme called a homing endonuclease that can target long sequences and is used to insert or delete DNA. The Durham, North Carolina-based companys fully synthetic version can be designed to locate and disrupt particular sequences and minimize off-target effects.

Gileads preliminary, in vitro studies using ARCUS nucleases had shown significant activity against cccDNA and integrated HBV DNA in human liver cells. But, two years down the line, Gilead no longer wants in.

Precision, which is predominately working on next-gen cancer therapies, will regain the license to its hep B program. Its not clear what prompted the decision, but the biotech could be on the lookout for a new partner.

This was a highly productive and well-aligned collaboration, and we deeply value the opportunity to advance our ARCUS genome editing technology and a potential cure for HBV alongside a global leader in infectious disease, said Derek Jantz, Ph.D., co-founder and chief scientific officer of Precision.

Key learnings from this program and how to develop liver-directed gene editing therapeutic candidates are directly applicable to our in vivo pipeline. While we consider new partnership opportunities for HBV, we are focused on progressing our internal lead proprietary gene correction program for primary hyperoxaluria type 1 for which we expect to nominate a clinical candidate later this year.

Go here to see the original:

Gilead axes $445M Precision Biosciences gene therapy hep B pact - FierceBiotech

Tissue Engineering Gene Therapy Market Consumption Status and Prospects Professional Market Research Report 2025 – CueReport

Posted on by

The latest report on Tissue Engineering Gene Therapy Industry market gives a broad evaluation of the global Tissue Engineering Gene Therapy Industry market by categorizing it in terms applications, types, and regions. The report gives a detailed analysis on competitive era and strategies adopted by the business to become the leader of the market in a positive way. Further, the report gives an overview of current market dynamics by studying various key segments based on the product, types, applications, end-to-end industries and market scenario. Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry.

The Tissue Engineering Gene Therapy Industry market report provides a broad perspective of this business landscape and elaborates on the various factors that are impacting the revenue generation and growth. The study also enlists exhaustive analysis of the regional landscape as well as regulatory outlook. A detailed SWOT analysis alongside market drivers are analyzed and offered in the document.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/20152

Other details such as challenges & restraints faced by market players as well as new entrants in tandem with their individual impact on the remuneration of companies is highlighted. The study also analyzes the effect of COVID-19 disease outbreak on future remuneration and overall growth of the market.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/20152

Underlining the competitive scenario of the Tissue Engineering Gene Therapy Industry market:

Highlighting the geographical landscape of Tissue Engineering Gene Therapy Industry market:

Additional information comprised in the Tissue Engineering Gene Therapy Industry market report:

Key questions answered in the report:

What is the growth potential of the Tissue Engineering Gene Therapy Industry market?

Which product segment will grab a lions share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

What are the growth opportunities that may emerge in Tissue Engineering Gene Therapy Industry industry in the years to come?

What are the key challenges that the global Tissue Engineering Gene Therapy Industry market may face in future?

Which are the leading companies in the global Tissue Engineering Gene Therapy Industry Industry?

Which are the key trends positively impacting the market growth?

Which are the growth strategies considered by the players to sustain hold in the global Tissue Engineering Gene Therapy Industry market?

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/20152

Here is the original post:

Tissue Engineering Gene Therapy Market Consumption Status and Prospects Professional Market Research Report 2025 - CueReport

Latest Trends in Hemophilia Gene Therapy Market 2020, Research Report Covers Updated Data Considering Impact of Covid-19 on Share, Size and Future…

Posted on by

ReportsandMarkets newly added a research report on the Hemophilia Gene Therapy market, which represents a study for the period from 2020 to 2026. The research study provides a near look at the market scenario and dynamics impacting its growth. This report highlights the crucial developments along with other events happening in the market which are marking on the growth and opening doors for future growth in the coming years. Additionally, the report is built on the basis of the macro- and micro-economic factors and historical data that can influence the growth.

Furthermore, this report on the Hemophilia Gene Therapy market put foremost descriptive viewpoint over the market, its peer market, as well as its parent market. In order to achieve this, bottom-up and top-down approaches are adopted by the analysts and researchers for the estimation of segmental, global, and regional revenue along with its consumption volume. Further, these findings are validated from the primary research and by discussing with seniors working in the market.

The final report will add the analysis of the Impact of Covid-19 in this report Hemophilia Gene Therapyindustry.

Get The Sample Copy https://www.reportsandmarkets.com/sample-request/global-hemophilia-gene-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=dailyresearchchronicles&utm_medium=15

Key Players

The global Hemophilia Gene Therapymarket has been comprehensively analyzed and the different companies that occupy a large percentage of the market share in the regions mentioned have been listed out in the report. Industry trends that are popular and are causing a resurgence in the market growth are identified. A strategic profile of the companies is also carried out to identify the various subsidiaries that they own in the different regions and who are responsible for daily operations in these regions. Business data for each of the companies mentioned are covered in the report published on the Hemophilia Gene Therapymarket.

Major Companies Included in Report are Ultragenyx, BioMarin, Shire PLC, uniQure, Sangamo Therapeutics, Bioverativ, Freeline Therapeutics, and Spark Therapeutics

Research objectivesTo study and analyze the global Hemophilia Gene Therapyconsumption (value & volume) by key regions/countries, product type and application, history data from 2013to 2019, and forecast to 2026.To understand the structure of Hemophilia Gene Therapymarket by identifying its various subsegments.Focuses on the key global Hemophilia Gene Therapymanufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Hemophilia Gene Therapywith respect to individual growth trends, future prospects, and their contribution to the total market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Hemophilia Gene Therapysubmarkets, with respect to key regions (along with their respective key countries).To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.

Market segmentationHemophilia Gene Therapymarket is split by Type and by Application. For the period 2015-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on Hemophilia Gene Therapyoffered by the key players in the Global Hemophilia Gene TherapyMarket2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Hemophilia Gene TherapyMarket3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Hemophilia Gene TherapyMarket4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Hemophilia Gene TherapyMarket5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Hemophilia Gene TherapyMarket

The report answers questions such as:1. What is the market size of Hemophilia Gene Therapymarket in the Global?2. What are the factors that affect the growth in the Global Hemophilia Gene TherapyMarket over the forecast period?3. What is the competitive position in the Global Hemophilia Gene TherapyMarket?4. Which are the best product areas to be invested in over the forecast period in the Global Hemophilia Gene TherapyMarket?5. What are the opportunities in the Global Hemophilia Gene TherapyMarket?6. What are the modes of entering the Global Hemophilia Gene TherapyMarket?

Browse the Full Report @ https://www.reportsandmarkets.com/sample-request/global-hemophilia-gene-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=dailyresearchchronicles&utm_medium=15

TABLE OF CONTENT:

Chapter 1:Hemophilia Gene TherapyMarket Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Hemophilia Gene TherapyMarket Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Hemophilia Gene TherapyMarket Effect Factors Analysis

Chapter 12: GlobalHemophilia Gene TherapyMarket Forecast to 2026

About us

Our marketing research reports comprise of the best market analysis along with putting the right statistical and analytical information on the markets, applications, industry analysis, market shares, technology and technology shifts, important players, and the developments in the market. If you require any specific company, then our company reports collection has countless profiles of all the key industrial companies. All these reports comprise of vital information including the company overview, the company history, the business description, the key products & services, the SWOT analysis, the crucial facts, employee details, the locations and subsidiaries to name a few.

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serves our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

See the original post:

Latest Trends in Hemophilia Gene Therapy Market 2020, Research Report Covers Updated Data Considering Impact of Covid-19 on Share, Size and Future...

Gene Therapy Market Size Is Projected to Register a CAGR of 40.7% By 2025 – Jewish Life News

Posted on by

Gene Therapy Market Highlights

Global Gene Therapy Market is expected to register a CAGR of 40.7% during the forecast period of 2019 to 2025 and was valued at USD 524 million in 2018. Gene therapy is a technique in which a piece of DNA is incorporated into the cell via a vector. The key players are investing in the manufacturing of cell and gene therapy treatments due to its target specificity. The gene therapy is mainly of two types, somatic gene therapy, and germline gene therapy, depending on the type of cells its targets.

The growth of the global gene therapy market is attributed to various factors such as robust product pipeline, increasing investment by key players, and high prevalence of target diseases and demand for innovative medication. However, the high cost of product development and stringent regulatory policies are expected to curb the growth of the global gene therapy market. The global gene therapy market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8399

Gene Therapy Market Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of gene therapy and rising per capita healthcare expenditure. The gene therapy market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European gene therapy market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The gene therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing number of patients and raising awareness about the treatment methods, the market in Asia-Pacific is expected to be the fastest-growing. The gene therapy market in the Middle East & Africa has been divided into the Middle East and Africa.

Gene Therapy Market Segmentation

The global gene therapy market has been segmented based on product, indication, and end user.

The market, based on product, has been divided into kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo, imlygic, and others.

The global gene therapy market has on the basis of indication is segmented, into oncology, genetic diseases/ disorders, and others. The oncology segment is expected to hold the largest market share and to be the fastest-growing segment due to high prevalence of cancer and robust pipeline for cancer gene therapy.

The end-user segments of the market are hospitals & clinics, specialty treatment centers, and others. The hospitals & clinics segment is expected to hold the largest market share due to increasing number of hospitals. Also, hospitals are generally the first treatment choice for diseases.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/gene-therapy-market-8399

Gene Therapy Market Key Players

Some of the key players in the global gene therapy market are Amgen, Inc. (US), Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), uniQure N.V. (Netherlands), Orchard Therapeutics plc (UK), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), CEVEC (Germany), and Lonza (Switzerland).

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

More here:

Gene Therapy Market Size Is Projected to Register a CAGR of 40.7% By 2025 - Jewish Life News

5 FDA approval decisions to watch in the 3rd quarter – BioPharma Dive

Posted on by

The next few months could bring the first gene therapy for hemophilia, a new type of multiple myeloma drug and an additional treatment option for a devastating muscular condition.

The Food and Drug Administration is set to make decisions on approval of all three, as well as on a closely watched arthritis pill and the first oral drug for spinal muscular atrophy, between July and September.

A regulatory OK for Roctavian, BioMarin Pharmaceutical's experimental hemophilia A treatment, would be a particularly significant milestone the first gene therapy for one of the world's most well-known inherited diseases. Approvals for Roche's risdiplam, NS Pharma's viltolarsen, Gilead's filgotinib and GlaxoSmithKline's belantamab mafodotin would also be notable.

The list of experimental drugs slated for the FDA's review during the third quarter was originally longer, but the agency cleared three targeted cancer therapies months ahead of schedule. (Seattle Genetics' Tukysa, Novartis' Tabrecta and Eli Lilly's Retevmo were all approved in April and May.)

Even as it's moved quickly to approve new drugs, the FDA has acknowledged the strain resulting from the work the agency is doing to oversee COVID-19 vaccine and drug development. So far, new drug reviews haven't been heavily affected, but the FDA has warned they could be slowed.

The five experimental drugs are listed in order of the currently scheduled date by which the FDA has agreed to make a decision on approval.

Around a dozen drugmakers are developing multiple myeloma treatments that target a protein known as BCMA, which is found on nearly all malignant cells. GlaxoSmithKline looks to be in a position to get there first.

GSK's drug, called belantamab mafodotin, is an antibody-drug conjugate, designed to bind to the BCMA target and deliver a small chemotherapy payload to attack cancerous cells. The conjugate approach is employed by Seattle Genetics' Adcetris and Roche's Kadcyla for other types of blood cancer.

Behind belantamab mafodotin, however, several other BCMA-targeting therapies are nearing key milestones, including a CAR-T cell therapy from Bristol-Myers Squibb and Bluebird bio, as well as a bispecific antibody from Regeneron.

They would trail belantamab mafadotin if the GSK drug is approved by the FDA's target decision date sometime this month. But the rival therapies could potentially offer advantages in greater effectiveness or more manageable side effects. Notably, balantamab mafadotin is associated with an eye-related side effect called keratopathy.

The FDA's decision to approve Sarepta Therapeutics' Exondys 51 for Duchenne muscular dystrophy in 2016 was one of the most controversial in the agency's recent history. The drug, a type of genetic treatment known as "exon-skipping," was the first specifically cleared for patients with DMD.

Approval late last year of Sarepta's second drug Vyondys 53 for a different segment of DMD patients was nearly as dramatic, with the FDA reversing an initial rejection after the company appealed to more senior agency officials.

The FDA's review of a DMD treatment developed by NS Pharma, a little-known subsidiary of Japan's Nippon Shinyaku, promises to be less eventful.

NS' drug, called viltolarsen and designed to treat the same group of DMD patients as Vyondys 53, works similarly to both of Sarepta's drugs. Study results published in JAMA Neurology this past May suggest it might even work better than Vyondys 53, although comparing drugs across trials can be misleading.

Like Sarepta, however, NS is offering the FDA limited evidence to go on. The study supporting the drugmaker's application primarily tested whether viltolarsen increased the production of a key protein that's largely missing in children with DMD and, notably, lacked a placebo comparison.

Having cleared Exondys 51 and then Vyondys 53, however, the FDA seems to have signaled it will accept early data as compelling enough to merit approval. A decision is expected sometime in August.

For Gilead and partner drugmaker Galapagos, much is riding on filgotinib. The drug is at the center of a research collaboration between the two companies, first inked in 2015 and then expanded with a $5.1 billion pact last year.

Part of a class of drugs called JAK inhibitors, filgotinib is aimed first at rheumatoid arthritis, a chronic condition for which it will have much competition. Three other JAK inhibitors, Pfizer's Xeljanz, Eli Lilly's Olumiant and AbbVie's Rinvoq, are already approved for rheumatoid arthritis, which is also commonly treated with biologic drugs like Humira.

Some analysts on Wall Street see filgotinib as safer than its JAK-blocking rivals, but the FDA appears to be viewing the risk of blood clots as characteristic of the drug class.

Gilead and Galapagos still think filgotinib can stand out and are counting on an August approval from the FDA to prove it. Clearance for rheumatoid arthritis would be the first step in proving the drug's future for other inflammatory conditions, like Crohn's disease, uveitis and psoriatic arthritis.

An approval for BioMarin's Roctavian would be a significant moment for the still-emerging gene therapy field. The experimental hemophilia A treatment wouldn't be the first gene therapy to gain FDA clearance that milestone went to Luxturna for an inherited form of blindness but it would offer thousands of patients long-lasting control of a disruptive and damaging bleeding disorder.

Roctavian also typifies the substantial benefits gene therapy can offer. Studies showed the treatment largely eliminated bleeding episodes, enabling patients to drastically reduce how much they rely on expensive factor replacement therapy that aids blood clotting. Years later, patients who received the treatment are still largely free of both.

BioMarin has suggested a price for Roctavian as high as $3 million, arguing the drug's value is clear when factor replacement therapy can sometimes cost as much as $1 million per year for severe hemophilia patients.

The company recently detailed follow-up data up to four years post-treatment in patients who were enrolled in early clinical trials. While their levels of blood clotting activity appear to decline over time, they are all still producing the Factor VIII protein that's reduced or missing in patients with hemophilia.

Spinal muscular atrophy, or SMA, is an often-fatal neuromuscular condition that primarily affects infants and children. Until three and a half years ago, there was no treatment.

An approval for Roche and PTC Therapeutics' risdiplam, expected by August 24, would bring to market the third treatment for the disease and the first one taken orally, which may be more convenient for some patients.

The companies have played up risdiplam's advantages compared to Spinraza, the first SMA drug, as well as versus Novartis' gene therapy Zolgensma. Spinraza is administered via a spinal injection, while Zolgensma is infused intravenously for treating infants.

Roche and PTC sought to submit to the FDA study data covering a broad range of patients, from infants to adults and across various levels of disease severity. In doing so, however, they caused the agency to extend its approval review by three months in order to take into account results from a study in less severe adolescents and adults.

See the original post:

5 FDA approval decisions to watch in the 3rd quarter - BioPharma Dive

Covid-19 Impact On Cell and Gene Therapy Market 2020: Global Industry Overview By Top Key Players Analysis And Growth Factors Up To 2025 | Amgen Inc.,…

Posted on by

Cell and Gene Therapy Market 2020: Latest Analysis

Chicago, United States:-TheCell and Gene Therapy market report5 Years Forecast [2020-2025]focuses on theCOVID19 Outbreak Impact analysis of key points influencing the growth of the market. The research report on the Cell and Gene Therapy Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the Cell and Gene Therapy market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the Cell and Gene Therapyindustry. Growth of the overall Cell and Gene Therapymarket has also been forecasted for the period 2020-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Top Players of Cell and Gene Therapy Market are studied:[ Amgen Inc., bluebird bio, Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cells Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS ]

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Cell and Gene Therapy Market:

What Our Report Offers:

Note: Covid-19 pandemic affects most industries in the globe. Here at acquire market research we offer you comprehensive data of related industry which will help and support your business in all possible ways.Due to the pandemic of COVID-19 businesses have seen a decrease in their profits. While our intention is to help businesses regain their profits we also provide information regarding the COVID-19 virus to help our customers stay safe during the pandemic

Cell and Gene TherapySegmentation by Product

General Type

Cell and Gene TherapySegmentation by Application

Pharmaceutical and Biotechnology CompaniesResearch and Academic Institutions

Benefits of Buying this Market Research Report:

Our exploration specialists acutely ascertain the significant aspects of the global Cell and Gene Therapy market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Cell and Gene Therapy market situation. In this Cell and Gene Therapy report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Cell and Gene Therapy report comprises of primary and secondary data which is exemplified in the form of pie outlines, Cell and Gene Therapy tables, analytical figures, and reference diagrams. The Cell and Gene Therapy report is presented in an efficient way that involves basic dialect, basic Cell and Gene Therapy outline, agreements, and certain facts as per solace and comprehension.

Table of Contents.

Report Overview:It includes major players of the globalkeywordmarket covered in the research study, research scope, and market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the globalkeywordmarket. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the globalkeywordmarket are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the globalkeywordmarket by application, it gives a study on the consumption in the globalkeywordmarket by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the globalkeywordmarket are profiled in this section. The analysts have provided information about their recent developments in the globalkeywordmarket, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the globalkeywordmarket as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the globalkeywordmarket as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the globalkeywordmarket.

Key Findings:This section gives a quick look at the important findings of the research study.

Get Full Customize report @ https://www.reporthive.com/request_customization/2369809

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

Continue reading here:

Covid-19 Impact On Cell and Gene Therapy Market 2020: Global Industry Overview By Top Key Players Analysis And Growth Factors Up To 2025 | Amgen Inc.,...

Covid-19 Outbreak: Gene Therapy for Age-related Macular Degeneration Market Insights and Forecast 2020 to 2025 – Owned

Posted on by

The study on the Gene Therapy for Age-related Macular Degeneration Marketby Brand Essence Market Research is a compilation of systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also offers a precise analysis of the key challenges and growth prospects awaiting key players of the Gene Therapy for Age-related Macular Degeneration market, including a concise summary of their corporate strategies and competitive setting.

In 2018, the Global Gene Therapy for Age-related Macular Degeneration Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Download Premium Sample of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=11998&RequestType=Sample

Latest research report on Gene Therapy for Age-related Macular Degeneration Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the markets growth.

The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

This report focuses on the global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.

The key players covered in this study RetroSense Therapeutics REGENXBIO AGTC

Market segment by Type, the product can be split into Subretinal Intravitreal Unspecified

Market segment by Application, split into Monotherapy Combination Therapy

In this study, the years considered to estimate the market size of Gene Therapy for Age-related Macular Degeneration are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

Market segment by Regions/Countries, this report covers United States Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. To present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by product type, market and key regions.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (2014-2025)1.4.2 Topical Products1.4.3 Botulinum1.4.4 Dermal Fillers1.4.5 Chemical Peels1.4.6 Microabrasion Equipment1.4.7 Laser Surfacing Treatments1.5 Market by Application1.5.1 Global Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2025)1.5.2 Hospitals1.5.3 Dermatology Clinics1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Gene Therapy for Age-related Macular Degeneration Market Size2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Regions2.2.1 Gene Therapy for Age-related Macular Degeneration Market Size by Regions (2014-2025)2.2.2 Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2014-2019)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Opportunities

3 Market Share by Key Players3.1 Gene Therapy for Age-related Macular Degeneration Market Size by Manufacturers3.1.1 Global Gene Therapy for Age-related Macular Degeneration Revenue by Manufacturers (2014-2019)3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Manufacturers (2014-2019)3.1.3 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)3.2 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served3.3 Key Players Gene Therapy for Age-related Macular Degeneration Product/Solution/Service3.4 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market3.5 Mergers & Acquisitions, Expansion Plans

Read More: https://industrystatsreport.com/Lifesciences-and-Healthcare/Dynamic-Growth-On-Gene-Therapy-for-Age-related-Macular-Degeneration-Market-Size-and-Share/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Top Trending Reports:

https://teletype.in/@gunjanjadhav/Flbjoxbde

https://penzu.com/journals/22918351/55339603

https://teletype.in/@gunjanjadhav/lC68kSQLT

https://teletype.in/@preranajoshi/uL2GCIVx6

https://teletype.in/@preranajoshi/zrTieEpyl

More:

Covid-19 Outbreak: Gene Therapy for Age-related Macular Degeneration Market Insights and Forecast 2020 to 2025 - Owned

Beefed-up rosters give Cardinals opening to flex versatility, depth of bullpen – The Salem News

Posted on by

Whenever, however he was being used in a game or, in the past few months, throwing bullpens with catcher Yadier Molina in Florida, rookie Junior Fernandez referred to a note he and pitching coach Mike Maddux committed to paper and he committed to using as a compass.

It reminds him regardless of the situation, regardless of the opponent, and regardless of the spot in the game to pitch to his strengths.

Now that Im here Im ready for everything, Fernandez said Friday evening at Busch Stadium. Here you have to be ready for everything any role, any time they call, any time they say youve got to be ready, youve got the next guy. With the plan that I set up, it doesnt matter who I face, doesnt matter what inning I pitch. Im always ready, and I come with the mindset that nobody can hit against me. Pitch with my strengths.

The note gives him direction.

That should help in a shortened season that will start backward and inspire teams to consider reverse-engineering games from the bullpen forward. The 60-game sprint for the postseason starts with a dash of September in July. Rather than end the season with expanded rosters, clubs will begin that way opening with a 30-man roster, as many as 17 pitchers, and handfuls of reasons to go sooner and more often to a deeper bullpen.

Its definitely more backwards than any of us are used to in our game, manager Mike Shildt said. But so are our circumstances. And we adjust and figure it out. I do feel like our ability to understand that weve got a bit more moving parts, with a more abbreviated spring training (makes) sense and literally guys get their legs under them. I feel like our approach is fairly aggressive. With more options, I could see the point of it, allowing for more aggressiveness knowing the next day youre got protection.

Added starter Adam Wainwright: You could definitely make a case coming right out of the chute that every game, every single game matters more than it normally does. It really matters now. Its almost like September baseball right away.

After facing hitters for a second time since Summer Camp opened a week ago at Busch, Wainwright echoed a sentiment that brings the Cardinals socially distant clubhouse together the teams pitching. The Cardinals feel they can identify as many as seven or eight starting pitchers for the rotation, and while they may go with 16 or 17 pitches to start the season theyll still have velocity and upside stashed at the alternate-site camp in Springfield, Mo.

Who they choose for the expanded roster is almost secondary to how they use what they have in the bullpen. The length that Austin Gomber and Daniel Ponce de Leon give the Cardinals could allow them carve up the first two thirds of games and then turn to the lightning and lefties they have with rookies like Fernandez and Kodi Whitley to pair with John Gant, Tyler Webb, and Andrew Miller. Prospect Johan Oviedo, who will start Saturdays intrasquad game opposite Carlos Martinez, offers another 98-mph option with a slider who is being readied to handle the innings of a starter.

I think we will be able to pass the ball around, Shildt said, quoting pitching coach Mike Maddux.

Wainwright used a term for his work the past few months that also fits.

A great science fair experiment, he said.

The Cardinals have as deep a pitching staff as any club in the National League Central, but also have a mix of acids and bases when it comes to pitches that give Shildt a different chemistry to utilize. On Friday night, Gant and Fernandez faced hitters in live batting practice and that meant Gants plunging changeup was followed by Fernandezs biting slider. The contrasts the Cardinals can show opponents grow from there.

During the sim game Thursday night, Shildt considered linking Dakota Hudson and Ponce de Leon so that one of the leagues top sinkerball pitchers was followed by Ponce de Leon and his elevated fastball. Thats a one-two, sink-rise, down-up combo the Cardinals could show opponents in their first two turns through the lineup to fiddle with eye levels. Genesis Cabrera remains absent from camp as he quarantines following a positive COVID-19 test, but when he returns he could bring his 98-mph sinker from the left side in after Wainwrights curveball-cutter combo from the right. Miles Mikolas relentless pursuit of strikes from the right would allow Gombers mix of breaking pitches from the left to look that much different.

Shildt has a zig to follow every zag, a left for every Wainwright.

Thats a real advantage. Its inherently an advantage, Shildt said. Guys present different looks and have different ways that they can compete and beat the other team. Its a mindset of how these guys can complement and give different looks. So it is nice the depth is important, but also the different skill sets are an added bonus.

Those skill sets also include the accordion relievers like Gant and Ponce de Leon each of whom has experience as a starter lugging innings and as a reliever quieting them.

Gant called it uncharted territory with the shortened season and the likelihood teams will be more assertive in games. Its possible some series turn upside down with relievers pitching more innings than starters. Gant echoed the note Fernandez keeps with about being ready for any situation and being open to pitch at the end of the game, great. If thats at the beginning of the game, great. If that is in the middle of the game, great.

More than just the roster numbers will be enhanced to start this season dropping from 30 to 28 after two weeks and then 26 for the final month of the season. The gravity of games could be, too. Each game this season is worth almost three in a 162-game schedule. That inflates the value of a lead, too, meaning an October-like approach that shifts from holding a lead late to coming in earlier and holding a lead longer.

An expanded roster and the flexibility of the bullpen gives the Cardinals the manpower to do that.

Were going to manage to win games. We always do, Shildt said. I do get the math. Its relative, too, right? Candidly, at this level, any game you manage youre managing to win that game. We may have to get to the end a little bit different relative to guys being built up but the fact of the matter is were getting to the end with a sense of urgency every day.

Cardinals pitcher Adam Wainwright throws to live batters during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher Kwang Hyun Kim throws to live batters during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals' Dexter Fowler throws a ball in from the outfield during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher John Gant fist bumps pitching coach Mike Maddux after a pitching session during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher Kwang Hyun Kim, right, and pitching prospect Johan Oviedo head to the mound during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher Adam Wainwright throws to live batters during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher John Gant throws to live batters during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

The sun dips below the stadium on the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher Junior Fernandez, left, talks with catcher Jose Godoy during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher Kwang Hyun Kim heads back to the dugout after a pitching session during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals' pitching prospect Johan Oviedo waits to swap rosin bags between pitchers during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher Junior Fernandez throws to live batters during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals' catcher Yadier Molina acts as a base runner during pithing practice on the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Temperatures began to dip at the end of practice after being around 91 degrees at the start. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals' pitcher Carlos Mart?nez waves to teammates from the stands on his way to the clubhouse during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher Adam Wainwright throws to live batters during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals' Rangel Ravelo fields a ground ball on the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

A player walks in front of "Summer Camp" signage on the seventh day of practice at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

A group of Cardinals go through base stealing drills in the outfield during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals' catcher Yadier Molina walks on the field during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals pitcher Kwang Hyun Kim throws to live batters during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Cardinals' Lane Thomas catches a ball during the seventh day of "Summer Camp" at Busch Stadium in St. Louis on Friday, July 10, 2020. Photo by Colter Peterson, cpeterson@post-dispatch.com

Original post:

Beefed-up rosters give Cardinals opening to flex versatility, depth of bullpen - The Salem News